CliffBio
small molecule

COGNEX

TACRINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyShionogi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCOGNEX
Active ingredientTACRINE HYDROCHLORIDE
StrengthEQ 20MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 1993
Marketing statusDISCN

More from Shionogi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

COGNEX patent cliff — loss of exclusivity — | CliffBio